BridgeBio Pharma's revenue for the
three
months ended in Mar. 2026 was €168.3 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €498.6 Mil.
BridgeBio Pharma's Revenue per Share for the
three
months ended in Mar. 2026 was €0.86.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €2.58.
During the past 12 months, the average Revenue per Share Growth Rate of BridgeBio Pharma was 348.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 70.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 70.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 9 years, BridgeBio Pharma's highest 3-Year average Revenue per Share Growth Rate was 70.70% per year. The lowest was -6.60% per year. And the median was 23.05% per year.
BridgeBio Pharma (FRA:2CL) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BridgeBio Pharma Revenue Related Terms
BridgeBio Pharma Revenue Historical Data
* Premium members only.
The historical data trend for BridgeBio Pharma's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BridgeBio Pharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Revenue distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €498.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (FRA:2CL) has a Revenue of €498.6 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on BridgeBio Pharma and its competitors.
Is BridgeBio Pharma's Revenue too high?
BridgeBio Pharma's current Revenue is €498.6 Mil. Overall, BridgeBio Pharma has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Revenue compare to EXEL and IONS?
BridgeBio Pharma's Revenue of €498.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on BridgeBio Pharma and its competitors. BridgeBio Pharma's current Revenue is €498.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €126.29, compared to a current price of €76.60 — trading 39.3% below its estimated fair value. The current Revenue is €498.6 Mil. BridgeBio Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Revenue is €498.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?
Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued.
The current stock price of €76.60 is trading 39.3% below its estimated GF Value™ of €126.29.
GuruFocus considers BridgeBio Pharma to be Possible Value Trap.
Key valuation signals for FRA:2CL:
Revenue: €498.6 Mil
GF Value™: €126.29 vs. price of €76.60 (39.3% below fair value)
No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
71GF Score
Get the complete analysis for FRA:2CL
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2CL has been successfully added to your 
